浙江昂利康制药股份有限公司股票交易异常波动公告

Group 1 - The stock of Zhejiang Anglikang Pharmaceutical Co., Ltd. experienced an abnormal trading fluctuation, with a cumulative closing price increase exceeding 20% over two consecutive trading days (June 6 and June 9, 2025) [1] - The company's board confirmed that there are no undisclosed significant matters that could impact the stock price, and previous disclosures do not require correction or supplementation [2][3] - The company is currently conducting a clinical trial for its innovative drug project ALK-N001, which received approval in April 2025 and is in the I phase of clinical trials [1][3] Group 2 - The company has verified that its operational status remains normal, with no significant changes in its main business or external operating environment [1] - The board has not identified any undisclosed information that should be disclosed according to the Shenzhen Stock Exchange regulations [2] - The company emphasizes the long development cycle and high investment required for innovative drug research, highlighting the inherent uncertainties and risks involved [3]